mRNA/saRNA Manufacturing RNA Production & Manufacturing

Aldevron Chief Scientific Officer, Venkata Indurthi, Ph.D., shared his knowledge and experience with manufacturing RNA in a webinar entitled, “mRNA/saRNA Manufacturing – Considerations to Accelerate the Path to Clinic.” As a follow up, Dr. Indurthi sat down with Communications Sr. Director, Ellen Shafer, for an interview to answer dozens of questions he received during the presentation.

Dr. Indurthi discusses key considerations for RNA production and manufacturing and how to strategize for successful commercial scaling. While RNA was always relevant and valued as a modality, the COVID-19 pandemic served as a catalyst and accelerated the field by 10-to-15 years. The development lifecycle was significantly reduced and now typically takes 6 to 9 months. It is crucial to understand and define the parameters of molecular design and behavior for your unique therapy product, a process which entails putting the molecule through the standard purification process to get the least amount of impurity and the highest amount of activity of the RNA.

Designing early processes to scale properly is key, and ensuring your enzyme of choice is achieving 100% linearization is the most important quality control assay that you have to do before taking the linearized plasmid and going into IVT manufacturing. Learn more about messenger RNA (mRNA) and self-amplifying RNA (saRNA) development and manufacturing processes and how different projects' needs may vary.